文献速递浆细胞疾病

达雷妥尤单抗单药治疗重度经治复发或难治性多发性骨髓瘤患者:2期GEN501和SIRIUS试验最终结果

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
PubMed 文献 · Lancet Haematol · 2020-01-01

本文汇总GEN501和SIRIUS两项研究中接受达雷妥尤单抗16 mg/kg单药治疗的148例重度经治复发或难治性多发性骨髓瘤患者进行事后最终分析。总缓解率为30.4%(95% CI 23.1-38.5),中位缓解持续时间8.0个月(95% CI 6.5-14.7),中位总生存20.5个月(95% CI 16.6-28.1)。延长随访未发现新的安全性问题。

要点

  • 148例患者接受达雷妥尤单抗16 mg/kg单药治疗,总缓解率30.4%(95% CI 23.1-38.5)。
  • 中位缓解持续时间8.0个月(95% CI 6.5-14.7),中位总生存20.5个月(95% CI 16.6-28.1)。
  • 最常见3-4级治疗中出现的不良事件为贫血(3级26例[18%])和血小板减少(3级13例[9%],4级8例[5%])。

核心结论

  • 达雷妥尤单抗16 mg/kg单药治疗在重度经治复发或难治性多发性骨髓瘤患者中显示持久缓解,延长随访未发现新的安全性问题。

研究设计与样本

  • GEN501为在荷兰、美国、瑞典和丹麦开展的非盲、多中心、1-2期剂量递增和扩展研究。
  • SIRIUS为在加拿大、西班牙和美国开展的非盲、多中心、2期研究。
  • 汇总事后最终分析纳入148例接受达雷妥尤单抗16 mg/kg治疗的患者(GEN501第2部分42例;SIRIUS 106例),中位随访36.6个月(IQR 34.5-38.2)。
  • 患者既往接受中位5线治疗(IQR 4-7),148例中128例(87%)为双重难治。

主要发现

  • 总缓解率为30.4%(95% CI 23.1-38.5),其中20例(14%)达非常好的部分缓解或更好(95% CI 8.5-20.1),7例(5%)达完全缓解或更好(95% CI 1.9-9.5)。
  • 45例缓解者的中位缓解持续时间为8.0个月(95% CI 6.5-14.7)。
  • 中位总生存为20.5个月(95% CI 16.6-28.1),3年总生存率为36.5%(95% CI 28.4-44.6)。
  • 最常见的3-4级治疗中出现的不良事件为贫血(3级26例[18%],无4级事件)和血小板减少(3级13例[9%],4级8例[5%])。
  • 严重药物相关治疗中出现的不良事件发生于148例中13例(9%),无治疗相关死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a pooled, post-hoc final analysis of these two studies. METHODS: GEN501 was an open-label, multicentre, phase 1-2, dose escalation and expansion study done in the Netherlands, the USA, Sweden, and Denmark. Eligible patients had multiple myeloma and had relapsed or were refractory to 2 or more previous lines of treatment that included a proteasome inhibitor or an immunomodulatory drug. SIRIUS was an open-label, multicentre, phase 2 study done in Canada, Spain, and the USA, in which eligible patients with multiple myeloma had received 3 or more previous lines of therapy, including a proteasome inhibitor or an immunomodulatory drug, or were double refractory. In both studies, eligible patients were aged 18 years or older and had an Eastern Cooperative Oncology Group performance status of 2 or less. In part 2 of GEN501, patients were given intravenous daratumumab 16 mg/kg once per week for 8 weeks, twice per month for 8 doses, and then once per month until disease progression. In part 2 of SIRIUS, patients received intravenous daratumumab 16 mg/kg once per week for 8 weeks, twice per month for 16 weeks, and once per month until disease progression. The primary endpoints (safety in GEN501 and overall response rate in SIRIUS) have previously been reported. These trials are registered on ClinicalTrials.gov, NCT00574288 (GEN501) and NCT01985126 (SIRIUS). FINDINGS: Patients were enrolled in GEN501 from March 27, 2008, until May 30, 2014, and in SIRIUS from Sept 30, 2013, until May 5, 2014. The combined analysis included 148 patients who received daratumumab 16 mg/kg (42 patients in GEN501 part 2; 106 patients in SIRIUS), with a median follow-up of 36·6 months (IQR 34·5-38·2). Patients had received a median of 5 previous lines of therapy (IQR 4-7), and 128 (87%) of 148 patients were double refractory. The overall response rate was 30·4% (95% CI 23·1-38·5), including 20 (14%) of 148 patients with very good partial response or better (8·5-20·1) and seven (5%) patients reporting complete response or better (1·9-9·5). Among 45 responders, the median duration of response was 8·0 months (95% CI 6·5-14·7). Median overall survival was 20·5 months (95% CI 16·6-28·1), with a 3-year overall survival rate of 36·5% (28·4-44·6). The most common grade 3-4 treatment-emergent adverse events (TEAEs) were anaemia (grade 3, 26 [18%] of 148 patients; no grade 4 events) and thrombocytopenia (grade 3, 13 [9%] of 148 patients; grade 4, 8 [5%] of 148 patients). Serious drug-related TEAEs occurred in 13 (9%) of 148 patients. There were no treatment-related deaths. INTERPRETATION: In this analysis, daratumumab 16 mg/kg monotherapy showed durable responses and there were no new safety concerns with longer follow-up. FUNDING: Janssen Research & Development.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Usmani SZ, Nahi H, Plesner T, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020. PMID: 32470437. doi:10.1016/S2352-3026(20)30081-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。